NEW YORK, NY, Sept. 14 /PRNewswire-FirstCall/ - - GENova Biotheropeutics, Inc., (“GENova”), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Wang Chong to its Scientific Advisory Board.
Dr. Wang Chong will contribute his considerable expertise to the company as it pursues its mandate to develop, patent and commercialize ground-breaking cancer-fighting biotechnologies, with a focus on breast and prostate cancer.
Aaron Whiteman, CEO of GENova stated, “GENova is proud to have attracted such an esteemed me member of the healthcare industry to assist us in our growth plans.”
About Dr. Wang Chong
Dr. Wang Chong is a physician with over 19 years of experience in the healthcare industry, whose expertise lies in raising capital for and listing small to medium-sized companies. Previous positions include CFO and Commercial Director of Phytopharm plc, CEO of Osmetech plc, Life Sciences Analyst at Canaccord Capital (Europe) Ltd, Leader of UK Healthcare Initiatives at premier management consultants Arthur D. Little Inc, and commercial roles at Glaxo Wellcome plc and SmithKline Beecham plc. Chong graduated with a medical degree from King’s College London and a MBA from London Business School. He is also a Council Member of the Royal Society of Medicine’s Pharmaceutical Medicine Research Section and an Associate of the Securities and Investment Institute.
About GENova Biotherapeutics Inc.
GENova is positioning itself as the world’s leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com.
Forward Looking Statements
This document includes certain statements that may be deemed to be “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.
SOURCE GENova Biotherapeutics, Inc.
CONTACT: Investor Relations: Brian Cook, Windfall Communications LLC,
1-866-797-8703, info@windfallcommunications.com
